The roadmap is ready that in the next decade will allow Europe to revolutionize healthcare thanks to precision medicine: by exploiting the most recent scientific discoveries and new technologies for the study of the individual cells of the human body, it will always allow diagnosis. more precocious and personalized treatments for cancer, cardiovascular, neurological, chronic inflammatory and infectious diseases, with important repercussions on people’s health and savings for welfare.
The plan, which has already garnered the support of hundreds of doctors, researchers, entrepreneurs and policy makers, is featured in the journal Nature by the Lifetime consortium. Mini organs in test tubes, artificial intelligence, single cell imaging techniques: these are just some of the innovations the consortium focuses on, which brings together more than one hundred institutions including universities and research centers as well as 80 companies, coordinated by the Max Molecular Medicine Center Delbrueck of Berlin and the Curie Institute of Paris.
Italy also participates with a large group led by the State University of Milan with Giuseppe Testa and Massimiliano Pagani, teachers of Molecular Biology in the departments of Oncology and Hemato-Oncology and of Medical Biotechnology and Translational Medicine.
“Transforming healthcare through a precise understanding of the mechanisms by which a disease begins in each patient and develops over time remains an enormous challenge, but today we are finally beginning to see its feasibility”, comments Giuseppe Testa, full professor of Molecular Biology at the University. Statale di Milano, director of the Neurogenomics Center of Human Technopole and director of the Laboratory of High Definition Disease Models of the European Institute of Oncology (Ieo).
“We are preparing to choose how to project our country towards rebirth through the Recovery fund: here, LifeTime in this sense is a trace of how to do it, in the biomedical field, of how to open the future while remaining anchored to the needs of today than never before. they appeared to us with so much drama “.
Covid-19 could be one of the test beds of the new European strategy outlined by Lifetime, as underlined by Massimiliano Pagani, professor of molecular biology at the State University of Milan and head of the Ifom molecular oncology and immunology laboratory.
“In the Lifetime consortium there are many research groups that are already investigating the effects of Covid on individual organ cells to better understand the mechanisms of the disease and the therapeutic opportunities: the new coronavirus in a certain sense is a case study that could revolutionize the our way of interpreting and dealing with new situations, such as those that could arise in the future with the arrival of new pandemics “.
– .
